歌礼制药-B（01672）于2026年7月8日发布公告，内容显示公司当日于香港联交所回购普通股股份10万股，占公司已发行股本约0.0094%。回购价格介乎每股10.98港元至11.46港元，合计支付约1,119,010港元（折合约111.90万港元）。
根据公告，截至回购完成后，公司已发行股本（不包括库藏股）仍为1,061,370,845股，库藏股为7,084,210股。公司表示，本次回购在2026年6月29日获股东授权，当时公司获许可回购最多106,137,084股。截至公告日，累计已回购345,000股，占授权时公司已发行股本约0.0325%。
公告强调，上述回购符合香港联交所证券上市规则及相关法律法规要求。本次公告由公司秘书钟明辉签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.